Latest Articles

Publication Date
All News Scientific
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
Read Full Article
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView

ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView

Published: Feb. 27, 2026, 3:34 p.m.
Read Full Article
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView

ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView

Published: Feb. 27, 2026, 2:50 p.m.
Read Full Article
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan

Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer Stock Titan

Published: Feb. 27, 2026, 2 p.m.
Read Full Article
Systems-level actions of luteolin in female reproductive disorders: from molecular mechanisms to clinical translation.

Female reproductive disorders represent a major global health challenge. Despite their clinical heterogeneity, these conditions share core pathological mechanisms including oxidative stress, chronic inflammation, hormonal imbalance, metabolic dysfunction, extracellular matrix …

Published: Feb. 25, 2026, midnight
Read Full Article
PI3K/AKT/PTEN female reproductive disorders inflammation luteolin oxidative stress
Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." - lamilano.it

Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." lamilano.it

Published: Feb. 23, 2026, 5:18 p.m.
Read Full Article
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." - lamilano.it

Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." lamilano.it

Published: Feb. 23, 2026, 5:15 p.m.
Read Full Article
Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." - lamilano.it

Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." lamilano.it

Published: Feb. 23, 2026, 5:12 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!